Difference between revisions of "Vincristine (Oncovin)"
Jump to navigation
Jump to search
| Line 21: | Line 21: | ||
*[[Multiple myeloma]] | *[[Multiple myeloma]] | ||
*[[Neuroendocrine tumors]] | *[[Neuroendocrine tumors]] | ||
| + | *[[Penile cancer]] | ||
*[[Sarcoma]] | *[[Sarcoma]] | ||
*[[Small cell lung cancer]] | *[[Small cell lung cancer]] | ||
Revision as of 04:16, 29 July 2013
Also known as LCR, VCR, or Vincasar Pfs.
General information
Class/mechanism: Vinca alkaloid, inhibits microtubule formation in the mitotic spindle, causing cell cycle arrest in metaphase.[1][2]
Route: IV
Extravasation: vesicant
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Diseases for which it is used
- Acute lymphocytic leukemia
- Aggressive Non-Hodgkin lymphoma
- Bone cancer
- Central nervous system (CNS) cancer
- Chronic lymphocytic leukemia (CLL) and Small lymphocytic lymphoma (SLL)
- Follicular lymphoma
- HIV-associated lymphoma
- Hodgkin lymphoma
- Hodgkin lymphoma, nodular lymphocyte-predominant
- Mantle cell lymphoma
- Multiple myeloma
- Neuroendocrine tumors
- Penile cancer
- Sarcoma
- Small cell lung cancer
- Thymoma
- Transplant conditioning regimens
Patient drug information
- Vincristine (Oncovin) patient drug information (Chemocare)[3]
- Vincristine (Oncovin) patient drug information (UpToDate)[4]